# Portugal Chemicals Export Opportunities (HS 28-38)

![Yugalinks](https://www.yugalinks.com/trade/yugalinks-logo-v3-dark-mode.webp)

> Yugalinks sector export playbook

Explore Portugal HS 28-38 chemicals export opportunities, product portfolio, buyer markets, growth signals, and diversification opportunities.

## Overview

- Exporter: Portugal (PRT)
- Sector: Chemicals
- HS chapters: HS 28-38
- Latest trade year: 2024
- Sector exports: $1.5B
- Products: 36
- Buyer markets: 25
- Average CAGR: +19.1%
- Global sector size: $714.6B

## Product portfolio

| Product | Global size | Your exports | Opportunity | CAGR | Markets | Share |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| HS 300490 - Medicaments: consisting of mixed or unmixed products n.e.s. in heading no. 3004, for therapeutic or prophylactic uses, packaged for retail sale | $302.0B | $974.3M | $113.1B | +18.9% | 20 | +0.3% |
| HS 300215 - Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, put up in measured doses or in forms or packings for retail sale | $156.5B | $228.9M | $64.0B | +50.5% | 15 | +0.0% |
| HS 300214 - Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, mixed, put up in measured doses or in forms or packings for retail sale | $22.0B | $335.6K | $29.6B | -4.7% | 3 | +0.0% |
| HS 382499 - Chemical products, mixtures and preparations: n.e.c. heading 3824 | $21.8B | $2.9M | $16.2B | +21.6% | 7 | +0.0% |
| HS 300439 - Medicaments: containing hormones (but not insulin), adrenal cortex hormones or antibiotics, for therapeutic or prophylactic uses, packaged for retail sale | $26.0B | $106.0M | $15.8B | +19.0% | 8 | +0.2% |
| HS 300212 - Blood, human or animal, antisera, other blood fractions and immunological products: antisera and other blood fractions | $26.8B | $1.7M | $14.8B | -5.0% | 5 | +0.0% |
| HS 300220 - Vaccines: for human medicine | $13.3B | $2.3M | $13.1B | -6.8% | 4 | +0.0% |
| HS 293359 - Heterocyclic compounds: containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure, (other than malonylurea (barbituric acid) and its derivatives),and loprazolam, mecloqualone, methaqualone, zipeprol and salts thereof | $11.8B | $4.3M | $11.7B | +26.5% | 2 | +0.0% |
| HS 382600 - Biodiesel and mixtures thereof: not containing or containing less than 70% by weight of petroleum oils or oils obtained from bituminous minerals | $12.6B | $12.7M | $10.8B | -3.6% | 4 | +0.1% |
| HS 293499 - Nucleic acids and their salts, other heterocyclic compounds, n.e.c. in heading number 2934 | $13.4B | $12.6M | $8.5B | +11.6% | 3 | +0.1% |
| HS 300339 - Medicaments: containing hormones (excluding insulin), (but not containing antibiotics), for therapeutic or prophylactic uses, not packaged for retail sale | $3.4B | $501.7 | $6.7B | -8.3% | 1 | +0.0% |
| HS 382200 - Reagents: diagnostic or laboratory reagents on a backing and prepared diagnostic or laboratory reagents whether or not on a backing, other than those of heading no. 3002 or 3006: certified reference material | $15.1B | $1.1M | $6.3B | +26.3% | 3 | +0.0% |
| HS 290243 - Cyclic hydrocarbons: p-xylene | $8.5B | $3.4M | $6.3B | +66.1% | 1 | +0.0% |
| HS 293590 - Sulphonamides: n.e.c. in heading no. 2935 | $4.7B | $8.4M | $6.1B | +21.0% | 3 | +0.1% |
| HS 330210 - Odoriferous substances and mixtures: of a kind used in the food or drink industries | $4.4B | $270.7 | $6.0B | -4.7% | 1 | +0.0% |
| HS 330499 - Cosmetic and toilet preparations: n.e.c. in heading no. 3304, for the care of the skin (excluding medicaments, including sunscreen or sun tan preparations) | $14.9B | $4.8M | $5.9B | +28.7% | 2 | +0.0% |
| HS 290110 - Acyclic hydrocarbons: saturated | $2.9B | $763.9K | $5.1B | +48.1% | 2 | +0.0% |
| HS 293399 - Heterocyclic compounds: n.e.c. in headings no. 2933 | $6.9B | $18.9K | $5.0B | -9.8% | 1 | +0.0% |
| HS 293379 - Heterocyclic compounds: lactams: other than 6-hexanelactam (epsilon caprolactam) | $4.2B | $44.5K | $4.8B | +2.8% | 1 | +0.0% |
| HS 330300 - Perfumes and toilet waters | $6.6B | $13.1M | $4.0B | +4.6% | 2 | +0.4% |
| HS 381800 - Chemical elements: doped for use in electronics, in the form of discs, wafers or similar forms: chemical compounds doped for use in electronics | $5.7B | $1.0M | $3.3B | +27.0% | 2 | +0.0% |
| HS 293719 - Polypeptide hormones, protein hormones and glycoprotein hormones, their derivatives and structural analogues: other than somatotropin, (its derivatives and structural anaologues) and insulin and its salts | $2.3B | $61.0K | $3.1B | +41.5% | 1 | +0.0% |
| HS 290121 - Acyclic hydrocarbons: unsaturated, ethylene | $1.8B | $11.2M | $2.4B | +16.8% | 1 | +0.8% |
| HS 290531 - Alcohols: acyclic, diols: ethylene glycol (ethanediol) | $3.2B | $803.5 | $2.2B | -60.3% | 1 | +0.0% |
| HS 381512 - Catalysts, supported: reaction initiators, reaction accelerators and catalytic preparations, with precious metal or precious metal compounds as the active substance, n.e.c. or included | $3.1B | $14.7M | $2.1B | +46.5% | 1 | +0.5% |
| HS 293299 - Heterocyclic compounds: with oxygen hetero-atom(s) only, no lactones or unfused furan rings (hydrogenated or not) in the structure, other than isosafrole, 1-(1,3-benzodiaxol-5-yl) propan-2-one, piperonal, safrole, tetrahydrocannabinols (all isomers) | $2.4B | $244.5 | $2.0B | -12.8% | 1 | +0.0% |
| HS 300420 - Medicaments: containing antibiotics (other than penicillins, streptomycins or their derivatives), for therapeutic or prophylactic uses, packaged for retail sale | $3.8B | $48.5M | $1.9B | +19.3% | 1 | +1.3% |
| HS 284590 - Isotopes (excluding those of heading no. 2844): compounds, inorganic or organic, of such isotopes, whether or not chemically defined | $1.1B | $584.5 | $1.9B | +23.4% | 1 | +0.0% |
| HS 382319 - Industrial monocarboxylic fatty acids: acid oils from refining: (other than stearic acid, oleic acid or tall oil fatty acids) | $1.3B | $122.8K | $1.9B | +34.9% | 1 | +0.0% |
| HS 281820 - Aluminium oxide: other than artificial corundum | $2.2B | $2.4K | $1.8B | -33.8% | 1 | +0.0% |
| HS 370790 - Photographic goods: chemical preparations other than sensitised emulsions, put up in measured portions or put up for retail sale in a form ready for use | $2.2B | $139.3 | $1.8B | -4.8% | 1 | +0.0% |
| HS 380893 - Herbicides, anti-sprouting products and plant-growth regulators: not containing substances of 3808.50: put up in forms or packings for retail sale or as preparations or articles | $2.0B | $5.6M | $1.7B | +144.8% | 1 | +0.3% |
| HS 300670 - Pharmaceutical goods: Gel preparations designed to be used in human or veterinary medicine as a lubricant for parts of the body for surgical operations or physical examinations or as a coupling agent between the body and medical instruments | $1.2B | $108.4 | $1.4B | -24.8% | 1 | +0.0% |
| HS 291736 - Acids: aromatic polycarboxylic acids: terephthalic acid and its salts | $1.6B | $11.7K | $1.4B | -49.5% | 1 | +0.0% |
| HS 340220 - Washing and cleaning preparations: surface-active, whether or not containing soap (excluding those of heading no. 3401), put up for retail sale | $1.2B | $210.8K | $1.4B | +6.2% | 1 | +0.0% |
| HS 293722 - Steroidal hormones, their derivatives and structural analogues: halogenated derivatives of corticosteroidal hormones | $1.5B | $2.1M | $1.3B | +7.3% | 1 | +0.1% |

## Best markets

- USA, Puerto Rico and US Virgin Islands (USA): $111.5B calculated opportunity across 17 products.
- China (CHN): $39.6B calculated opportunity across 13 products.
- Germany (DEU): $39.1B calculated opportunity across 12 products.
- Switzerland, Liechtenstein (CHE): $37.8B calculated opportunity across 5 products.
- Belgium (BEL): $30.5B calculated opportunity across 6 products.
- Netherlands (NLD): $19.6B calculated opportunity across 5 products.
- Slovenia (SVN): $15.9B calculated opportunity across 3 products.
- Italy (ITA): $12.0B calculated opportunity across 3 products.
- Canada (CAN): $11.7B calculated opportunity across 6 products.
- Spain (ESP): $11.5B calculated opportunity across 6 products.
- United Kingdom (GBR): $11.1B calculated opportunity across 5 products.
- France (FRA): $10.3B calculated opportunity across 5 products.

## Growth stars

- HS 380893: +144.8% average CAGR, $1.7B calculated opportunity.
- HS 290243: +66.1% average CAGR, $6.3B calculated opportunity.
- HS 300215: +50.5% average CAGR, $64.0B calculated opportunity.
- HS 290110: +48.1% average CAGR, $5.1B calculated opportunity.
- HS 381512: +46.5% average CAGR, $2.1B calculated opportunity.
- HS 293719: +41.5% average CAGR, $3.1B calculated opportunity.
- HS 382319: +34.9% average CAGR, $1.9B calculated opportunity.
- HS 330499: +28.7% average CAGR, $5.9B calculated opportunity.
- HS 381800: +27.0% average CAGR, $3.3B calculated opportunity.
- HS 293359: +26.5% average CAGR, $11.7B calculated opportunity.

## Diversification opportunities

- HS 300490: 20 buyer markets, $113.1B calculated opportunity.
- HS 300215: 15 buyer markets, $64.0B calculated opportunity.
- HS 300439: 8 buyer markets, $15.8B calculated opportunity.
- HS 382499: 7 buyer markets, $16.2B calculated opportunity.
- HS 300212: 5 buyer markets, $14.8B calculated opportunity.
- HS 300220: 4 buyer markets, $13.1B calculated opportunity.
- HS 382600: 4 buyer markets, $10.8B calculated opportunity.
- HS 300214: 3 buyer markets, $29.6B calculated opportunity.
- HS 293499: 3 buyer markets, $8.5B calculated opportunity.
- HS 382200: 3 buyer markets, $6.3B calculated opportunity.

## Method

Reported trade observations and calculated indicators are shown separately. Validate buyers, standards, logistics, pricing, and competition before acting. [Read the Yugalinks methodology](https://www.yugalinks.com/methodology).

## Data sources

- Primary trade series: OECD (2025), Balanced international merchandise trade statistics (BIMTS) - HS2017-6D, OECD Data Explorer (accessed on 2026-08-30). [OECD Data Explorer](https://data-explorer.oecd.org/) - [OECD Terms & Conditions](https://www.oecd.org/termsandconditions/)
- CEPII BACI bilateral trade flows (202601): [dataset page](https://www.cepii.fr/CEPII/en/bdd_modele/bdd_modele_item.asp?id=37) - [BACI documentation](https://www.cepii.fr/DATA_DOWNLOAD/baci/doc/baci_webpage.html) - [Etalab 2.0 Open Licence](https://www.etalab.gouv.fr/wp-content/uploads/2018/11/open-licence.pdf)

This page presents derived Yugalinks views of reported observations and calculated indicators.